Liminal BioSciences Competitors and Similar CompaniesClear all
Liminal BioSciences's competitors and similar companies include Vertex Pharmaceuticals, Biogen, YiChang HEC ChangJiang Pharmaceutical and Cipla.
 Liminal BioSciences Liminal BioSciences is a biotechnology company developing small molecule compounds for respiratory, liver, and renal diseases. |  Vertex Pharmaceuticals Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  YiChang HEC ChangJiang Pharmaceutical YiChang HEC ChangJiang Pharmaceutical is a company that develops, manufactures, and sells pharmaceutical products. |  Cipla Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products. | |
Founding Date | Founding Date 1994 | Founding Date 1989 | Founding Date 1978 | Founding Date 2001 | Founding Date 1935 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Laval, CA HQ Pampisford, GB | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations HQ | Locations Mumbai, IN HQ Melbourne, AU Antwerpen, BE São Paulo, BR São Paulo, BR Unterhaching, DE Nairobi, KE see more | |
Employees | Employees 251 | Employees 5,40013% increase | Employees 7,605 | Employees 4,595 | Employees 27,764 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 121.4 b | Valuation ($) 26.7 b | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) $416k (FY, 2022) | Revenue (est.) $12b (FY, 2025) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) ¥3.7b (FY, 2024) | Revenue (est.) ₹277.1b (FY, 2026) |
Cost of goods | Cost of goods N/A | Cost of goods $1.7b (FY, 2025) | Cost of goods $2.4b (FY, 2025) | Cost of goods ¥533.6m (FY, 2024) | Cost of goods ₹95.5b (FY, 2026) |
Gross profit | Gross profit $416k (FY, 2022) | Gross profit $10.4b (FY, 2025) | Gross profit $7.5b (FY, 2025) | Gross profit ¥3.2b (FY, 2024) | Gross profit ₹195b (FY, 2026) |
Net income | Net income $1.2m (FY, 2022) | Net income N/A | Net income $1.3b (FY, 2025) | Net income ¥482.7m (FY, 2024) | Net income ₹38.7b (FY, 2026) |
Operating ⚠ | |||||
Products | Products N/A | Products 6 (FY, 2022) | Products N/A | Products N/A | Products 1.5 k (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 71.7m | Total funding raised $ 2.4m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Vertex Pharmaceuticals
HQ
Boston, US
Employees
5,400↑ 13% increase
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and producing medicines.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View companyYiChang HEC ChangJiang Pharmaceutical
HQ
Employees
4,595
YiChang HEC ChangJiang Pharmaceutical is a company that develops, manufactures, and sells pharmaceutical products.
View companyCipla
HQ
Mumbai, IN
Employees
27,764
Cipla is a pharmaceutical company focused on the development, manufacturing, and distribution of medications and healthcare products.
View company